Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubamatamab alone or with cemiplimab in recurrent MUC16-positive gynecologic cancers
NL-OMON60082Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ubamatamab and cemiplimab in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC) and 1 more (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 5 more. Started Jan 2024; status: recruiting.
02
Drugs
ubamatamabcemiplimab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON60082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60082.